Read by QxMD icon Read

Letrozole and carpal

J Huober, B F Cole, M Rabaglio, A Giobbie-Hurder, J Wu, B Ejlertsen, H Bonnefoi, J F Forbes, P Neven, I Láng, I Smith, A Wardley, K N Price, A Goldhirsch, A S Coates, M Colleoni, R D Gelber, B Thürlimann
There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of the BIG 1-98 clinical trial who did not have either vasomotor or arthralgia/myalgia/carpal tunnel (AMC) symptoms reported at baseline, started protocol treatment and were alive and disease-free at the 3-month landmark (n = 4,798) and at the 12-month landmark (n = 4,682) were used for this report...
January 2014: Breast Cancer Research and Treatment
Per Eystein Lønning, Hans Petter Eikesdal
Following their successful implementation for the treatment of metastatic breast cancer, the 'third-generation' aromatase inhibitors (anastrozole, letrozole, and exemestane) have now become standard adjuvant endocrine treatment for postmenopausal estrogen receptor-positive breast cancers. These drugs are characterized by potent aromatase inhibition, causing >98% inhibition of estrogen synthesis in vivo. A recent meta-analysis found no difference in anti-tumor efficacy between these three compounds. As of today, aromatase inhibitor monotherapy and sequential treatment using tamoxifen followed by an aromatase inhibitor for a total of 5 years are considered equipotent treatment options...
August 2013: Endocrine-related Cancer
N Lynn Henry, Jon A Jacobson, Mousumi Banerjee, Jill Hayden, Jeffrey B Smerage, Catherine Van Poznak, Anna Maria Storniolo, Vered Stearns, Daniel F Hayes
BACKGROUND: Nearly half of women treated with aromatase inhibitors (AI) develop AI-associated musculoskeletal symptoms (AIMSS) such as arthralgias, but to the authors' knowledge the etiology is unclear. The upper extremities are frequently affected, especially the wrists, hands, and fingers. AI use may also increase the risk of developing carpal tunnel syndrome. Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging symptomatic patients who were treated with AIs...
September 15, 2010: Cancer
Leilani Morales, Steven Pans, Robert Paridaens, Rene Westhovens, Dirk Timmerman, Johan Verhaeghe, Hans Wildiers, Karin Leunen, Frederic Amant, Patrick Berteloot, Ann Smeets, Erik Van Limbergen, Caroline Weltens, Walter Van den Bogaert, Luc De Smet, Ignace Vergote, Marie-Rose Christiaens, Patrick Neven
OBJECTIVE: Arthralgia, skeletal and muscle pain have been reported in postmenopausal women under treatment with third generation aromatase inhibitors (AIs). However, the pathogenesis and anatomic correlate of musculoskeletal pains have not been thoroughly evaluated. Moreover, the impact of AI-induced musculoskeletal symptoms on normal daily functioning needs to be further explored. PATIENTS AND METHODS: We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane...
July 2007: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"